Print

InDex Signs $35M Agreement With Serono For Inflammation 
10/19/2005 5:10:10 PM

InDex Pharmaceuticals AB signed its first product deal, out-licensing its antisense drug Kappaproct to Serono SA, of Geneva, for treatment of ulcerative colitis and other inflammatory conditions.
//-->